NEW YORK, March 08, 2018 -- The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Ohr Pharmaceutical, Inc. (NASDAQ:OHRP) who purchased shares between June 24, 2014 and January 4, 2018. The action, which was filed in the United States District Court for the Southern District of New York, alleges that the Company violated federal securities laws.
In particular, the complaint alleges that throughout the Class Period, defendants made materially false and/or misleading statements and/or failed to disclose that (1) Ohr’s lead product Squalamine would not produce vision improvements and was commercially not viable; and (2) as a result of the foregoing, Defendants’ statements about Ohr’s business, operations, and prospects were misleading and/or lacked a reasonable basis.
Shareholders have until April 16, 2018 to petition the court for lead plaintiff status. Your ability to share in any recovery does not require that you serve as lead plaintiff. You may choose to be an absent class member.
If you suffered a loss during the class period and wish to obtain additional information, please contact Joseph Klein, Esq. by telephone at 212-616-4899 or visit http://www.kleinstocklaw.com/pslra-c/ohr-pharmaceutical-inc?wire=3.
Joseph Klein, Esq. represents investors and participates in securities litigations involving financial fraud throughout the nation. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Joseph Klein, Esq.
Empire State Building
350 Fifth Avenue
59th Floor
New York, NY 10118
Telephone: (212) 616-4899
Fax: (347) 558-9665
www.kleinstocklaw.com


DBS Expects Slight Dip in 2026 Net Profit After Q4 Earnings Miss on Lower Interest Margins
Taiwan Says Moving 40% of Semiconductor Production to the U.S. Is Impossible
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates
Innovent Biologics Shares Rally on New Eli Lilly Oncology and Immunology Deal
Samsung Electronics Shares Jump on HBM4 Mass Production Report
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans
Salesforce Workforce Reduction Affects Fewer Than 1,000 Roles Amid Ongoing Restructuring
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil
Hims & Hers Halts Compounded Semaglutide Pill After FDA Warning
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns
Alphabet Plans Rare 100-Year Sterling Bond to Fund AI Expansion
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit
Amazon Explores AI Content Marketplace With Media Publishers
Macquarie Group Shares Jump as Third-Quarter Trading Conditions Improve Across Key Units
Indian Refiners Scale Back Russian Oil Imports as U.S.-India Trade Deal Advances
Kroger Set to Name Former Walmart Executive Greg Foran as Next CEO
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge 



